Last reviewed · How we verify
CG5503
CG5503 is a small molecule that targets the SGLT2 receptor.
CG5503 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | CG5503 |
|---|---|
| Sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, CG5503 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
Key clinical trials
- Effectiveness of Percutaneous Neuromodulation vs Pharmacological Treatment in Cancer Patients With Anterior Knee Pain (NA)
- OpioidRedoxStudyII
- Role of Preoperative Tapentadol in Reduction of Perioperative Analgesic Requirement After Breast Conservative Surgery in Cancer Patients. (NA)
- ACU_Knee: Role of Acupuncture in Knee Prosthetic Surgery (NA)
- IV vs Oral Acetaminophen in Spine Fusion Perioperative Care (PHASE4)
- Tapentadol Versus Oxycodone - a Mechanism-based Treatment Approach in Neuropathic Pain (PHASE4)
- Tapentadol vs Tramadol in Total Knee Arthroplasty (PHASE4)
- Postoperative Opioid and Respiratory Depression in Opioid Naive and Chronic Opioid Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CG5503 CI brief — competitive landscape report
- CG5503 updates RSS · CI watch RSS
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. portfolio CI